Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 7, 2005, Pages 365-374

  Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hormonal therapy; Prostate cancer; Prostate specific antigen; Radical prostatectomy; Recurrence; Salvage radiotherapy

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANTIGEN DETECTION; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL TRIAL; GLEASON SCORE; HUMAN; MALE; METASTASIS; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SIDE EFFECT; BLOOD; PROSTATE TUMOR; SALVAGE THERAPY; TUMOR RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 24944441859     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi113     Document Type: Review

References (93)

1. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994;152:1831-6.
2. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48:249-60.
3. Van den Ouden D, Hop WCJ, Kranse R, Schroder FH. Tumor control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997;79:203-11.
4. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
5. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
6. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-5.
7. Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152: 1837-42.
8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999;281:1591-7.
9. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
10. Stamey TA, Kabalin JN, McNeal JE, Johnstone M, Freiha F, Redwine EA, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076-83.
11. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: Update 1994. J Urol 1994;152:1358-68.
12. Presti JC Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998;52:1079-84.
13. Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 2002;168:110-5.
14. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic urologic research endeavor database. J Urol 2001;166:1322-7.
15. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consensus patients. J Urol 2002;167:528-34.
16. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001;165:1146-51.
17. Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 1999;161:163-8.
18. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 2003; 61:365-9.
19. Schild SE, Wong WW, Novicki DE, Ferrigni RG, Swanson SK. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology 1996;47:878-81.
20. Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, et al. EAU guidelines on prostate cancer. Eur Urol 2001;40:97-101.
21. Boccon-Gibod L, Djavan B, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: A European consensus. Int J Clin Pract 2004;58:382-90.
22. Oh J, Colberg JW, Ornstein DK, Johnson ET, Chan D, Virgo KS, et al. Current followup strategies after radical prostatectomy: A survey of American Urological Association urologists. J Urol 1999;161:520-3.
23. Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000;83:1432-6.
24. Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 1997;50:573-9.
25. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997;24:275-82.
26. Ornstein DK, Oh J, Hershman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 1998;25:591-601.
27. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. J Am Med Assoc 1997;277:1445-51.
28. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-8.
29. Partin AW, Mohler JL, Piantadosi S, Brendler CB, Sanda MG, Walsh PC, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-8.
30. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
31. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
32. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinant of cancer progression in men with prostate cancer. J Am Med Assoc 1999;281:1395-400.
33. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy; the Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-25.
34. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003;62:866-71.
35. Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt M-C, McLeod DG, Srivastava S, et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 1997;79:952-62.
36. Stapleton AMF, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT, et al. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998;82:168-75.
37. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, et al. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996;56:3814-22.
38. Yang RM, Naitoh J, Murphy M, Wang H-J, Phillipson J, deKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-5.
39. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-43.
40. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79:772-9.
41. Laufer M, Pound CR, Carducci MA, Eisenberger MA. Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 2000;55:309-15.
42. Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003;30:377-401.
43. Schellhammer PF, El-Mahdi AM. Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. Urol Clin North Am 1990;17:835-51.
44. Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carroll P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 1993;149:1024-8.
45. Wasserman NF, Kapoor DA, Hildebrandt WC, Zhang G, Born KM, Eppel SM, et al. Transrectal US in evaluation of patients after radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer. Radiology 1992;185; 367-72.
46. Saleem MD, Sanders H, Naser MAE, El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283-6.
47. Lightner DJ, Lange PH, Reddy PK, Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 1990;144:921-6.
48. Obek C, Neulander E, Sadek S, Soloway MS. Is there a role for digital rectal examination in the followup of patients after radical prostatectomy? J Urol 1999;162:762-4.
49. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996;47:225-31.
50. Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD, et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specifc antigen and pathologic stage. Urology 1999;54:1044-8.
51. Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 2001;166:111-5.
52. Scattoni V, Roscigno M, Raber M, Consonni P, Pozzo LD, Rigatti P. Biopsy of the vesico-urethral anastomosis after radical prostatectomy: When and how. Eur Urol 2002;38(Suppl. 1):89-95.
53. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-91.
54. Johnstone PAS, Tarman GJ, Riffenburgh R, Rohde DC, Puckett ML, Kane CJ. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol 1997;3:108-12.
55. Hricak H, Schroder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 2003;30:616-34.
56. Harisinghani MG, Barentsz J, Hahn PF, Desrno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
57. Levesque PE, Nieh PT, Zinman LN, Seldin DW, Libertino JA. Radiolabeled monoclonal antibody indium 111-labeled cyt-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998;51:978-84.
58. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998;159:2041-7.
59. Lange PH. Prostascint scan for staging prostate cancer. Urology 2001;57:402-6.
60. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;159:173-8.
61. Partin AW, Pound CR, Pearson JD, Clemens JQ, Landis PK, Epstein JI, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-59.
62. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158:1441-5.
63. Egawa S, Matsumoto K, Suyama K, Soh S, Kuwano S, Iwamura M. Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology 1999;53:148-54.
64. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142:332-6.
65. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993;149:516-8.
66. Ornstein DK, Colberg JW, Virgo KS, Chan D, Johnson ET, Oh J, et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology 1998;52:1047-54.
67. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 1999;17:1155-63.
68. Haab F, Delmas V, Meulemans A, Hennequin C, Boccon-Gibod L, Benbunan D, et al. Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology 1995;45:1022-7.
69. Garg MK, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood DP, et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998;51:998-1002.
70. Crane CH, Rich TA, Read PW, Snfilippo NJ, Gillenwater JY, Kelly MD. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997;39:681-6.
71. Schild SE, Wong WW, Grado GL, Buskirk SJ, Robinow JS, Frick LM, et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994;69:613-9.
72. Kooy MJV, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 1997;49:65-70.
73. Nudell DM, Grossfeld GD, Weinberg VK, Roach M III, Carroll PR. Radiotherapy after radical prostatectomy: Treatment outcomes and failure patterns. Urology 1999;54:1049-57.
74. Peschel RE, Robnett TJ, Hesse D, King CR, Ennis RD, Schiff PB, et al. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int J Cancer 2000;90:29-36.
75. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21:483-9.
76. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. J Am Med Assoc 2004;291:1325-32.
77. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R, Strorme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
78. Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998;41:735-40.
79. Tsien C, Griffith KA, Sanderr HM, McLaughlin P, Sanda MG, Montie J, et al. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology 2003;62:93-8.
80. Peyromaure M, Allouch M, Eschwege F, Verpillat P, Debre B, Zerbib M. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: A study of 62 patients. Urology 2003;62:503-7.
81. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 1998;159:1988-92.
82. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
83. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Eng J Med 1984;311:1281-6.
84. Vogelzang NJ, Chodak GW, Soloway MS, Block NL, Schellhammer PF, Smith JA Jr, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial. Urology 1995;46:220-6.
85. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51:389-96.
86. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Poppel HV, Tammela TLJ, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-82.
87. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of 'casodex'™ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-56.
88. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
89. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K, et al. Bicaltamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004;172:1865-70.
90. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70.
91. Yokomizo A, Kawamoto H, Nihei K, Ishizuka N, Kakehi Y, Tobisu K, et al. Randomized controlled trial to evaluate radiotherapy ± endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol 2005;35:34-6.
92. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35(Suppl 1):27-31.
93. Andriole G, Rajfer J, Fradet Y, Lieber M, Boake R, Block N, et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491-7.